NCT05305300View on ClinicalTrials.gov

A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals

PHASE1CompletedINTERVENTIONAL

Enrollment

135

Participants

Timeline

Start Date

October 18, 2021

Primary Completion Date

May 15, 2022

Study Completion Date

September 15, 2022

Conditions

COVID-19 Pandemic

Interventions

BIOLOGICAL

PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm A

receive two doses of PIKA COVID-19 vaccine (5 μg S protein/1mg PIKA, 10μg S protein/1mg PIKA and 20μg S protein/1mg PIKA) via IM administration on Days 0 and 7.

BIOLOGICAL

PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm B

receive one dose of PIKA COVID-19 vaccine (5 μg S protein/1mg PIKA, 10μg S protein/1mg PIKA and 20μg S protein/1mg PIKA) via IM administration on Days 0.

Trial Locations (1)

Unknown

Al Kuwait Hospital (Al Baraha Hospital), Dubai

All Listed Sponsors

lead

Yisheng Biopharma (Singapore) Pte. Ltd.

INDUSTRY

NCT05305300 - A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals | Biotech Hunter | Biotech Hunter